4.7 Article

Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?

期刊

LEUKEMIA
卷 35, 期 4, 页码 1166-1175

出版社

SPRINGERNATURE
DOI: 10.1038/s41375-020-01092-2

关键词

-

资金

  1. Leukemia and Lymphoma Society Research Scholar Grant
  2. American Cancer Society Clinical Scholar Award
  3. NCI P01 Award [1P01CA229092-01A1]
  4. NCI/NIH T32 Grant [CA092203]

向作者/读者索取更多资源

The study found that in advanced MDS patients, early HCT or for adverse risk disease significantly improved survival, while the effect was not as significant for patients with standard risk disease and severe cytopenia.
We conducted a prospective observational study of fit adults aged 60-75 with advanced MDS, enrolled hierarchically for adverse MDS risk (intermediate-2 or high-risk international prognostic score [IPSS], low or intermediate-1 IPSS with poor-risk cytogenetics, or therapy-related MDS) or standard risk with severe cytopenia. A total of 290 patients enrolled at two centers: 175 for adverse risk and 115 for standard risk with severe cytopenia. 113 underwent HCT after a median of 5 months; median follow-up for all was 39.5 months. In univariable analyses, the hazard ratio (HR) for death comparing HCT with no HCT was 0.84 (p = 0.30). The HR for death was 0.64 (p = 0.04) for HCT <= 5 months after enrollment and 1.20 (p = 0.39) for HCT > 5 months. In multivariable analyses controlling for age, gender, ECOG performance status, cytogenetic risk, and IPSS risk group, HR for death was 0.75 (p = 0.13) for HCT compared to no HCT, 0.57 (p = 0.01) for adverse MDS risk and 1.33 (p = 0.36) for standard risk with severe cytopenia. In this large, prospective cohort of fit older adults with advanced MDS, we found that survival was significantly improved if HCT was performed early or for adverse risk disease but not for standard risk disease with severe cytopenia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据